Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Page 1
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
Elm JJ; NINDS NET-PD Investigators. Elm JJ, et al. Mov Disord. 2012 Oct;27(12):1513-21. doi: 10.1002/mds.25175. Mov Disord. 2012. PMID: 23079770 Free PMC article. Clinical Trial.
A randomized, multicenter, double-blind, parallel-group, placebo-controlled phase III study of creatine (10 g daily) in participants with early, treated PD, the Long-term Study-1 (LS-1), is being conducted by the National Institute of Neurological Disorders and Stroke Expl …
A randomized, multicenter, double-blind, parallel-group, placebo-controlled phase III study of creatine (10 g daily) in participants with ea …
Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage.
Quik M, Campos C, Parameswaran N, Langston JW, McIntosh JM, Yeluashvili M. Quik M, et al. Among authors: langston jw. J Mol Neurosci. 2010 Jan;40(1-2):105-13. doi: 10.1007/s12031-009-9265-9. Epub 2009 Aug 15. J Mol Neurosci. 2010. PMID: 19685015 Free PMC article.
Our previous work had shown that long-term nicotine administration improved dopaminergic markers and nicotinic receptors (nAChRs) in the striatum of monkeys with nigrostriatal damage. ...Nicotine also significantly elevated microglia and reduced the number of extracellular …
Our previous work had shown that long-term nicotine administration improved dopaminergic markers and nicotinic receptors (nAChRs) in …
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, Kim A, Tyndale RF, Langston JW, Di Monte DA. Quik M, et al. Among authors: langston jw. J Neurochem. 2006 Sep;98(6):1866-75. doi: 10.1111/j.1471-4159.2006.04078.x. Epub 2006 Aug 1. J Neurochem. 2006. PMID: 16882311 Free article.
The present studies were done to investigate the effect of long-term nicotine treatment against nigrostriatal damage in non-human primates. ...
The present studies were done to investigate the effect of long-term nicotine treatment against nigrostriatal damage in non-human pri …
Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T, Parameswaran N, Fan H, Langston JW, McIntosh JM, Quik M. Bordia T, et al. Among authors: langston jw. J Pharmacol Exp Ther. 2006 Oct;319(1):285-92. doi: 10.1124/jpet.106.106997. Epub 2006 Jul 12. J Pharmacol Exp Ther. 2006. PMID: 16837557
Recent studies in nonhuman primates show that chronic nicotine treatment protects against nigrostriatal degeneration, with a partial restoration of neurochemical and functional measures in the striatum. The present studies were done to determine whether long-term nicotine …
Recent studies in nonhuman primates show that chronic nicotine treatment protects against nigrostriatal degeneration, with a partial restora …
Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Quik M, Chen L, Parameswaran N, Xie X, Langston JW, McCallum SE. Quik M, et al. Among authors: langston jw. J Neurosci. 2006 Apr 26;26(17):4681-9. doi: 10.1523/JNEUROSCI.0215-06.2006. J Neurosci. 2006. PMID: 16641249 Free PMC article.
In contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotine. Long-term nicotine administration also attenuated the enhanced K(+)-evoked fractional dopamine release from synaptosomes of MPTP-l …
In contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotin …
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment.
McCallum SE, Parameswaran N, Bordia T, Fan H, Tyndale RF, Langston JW, McIntosh JM, Quik M. McCallum SE, et al. Among authors: langston jw. J Neurochem. 2006 Feb;96(4):1028-41. doi: 10.1111/j.1471-4159.2005.03646.x. Epub 2006 Jan 12. J Neurochem. 2006. PMID: 16412091 Free article.
Although nicotine is well known to up-regulate alpha4* nAChR sites and function in the cortex, its actions in the striatum are uncertain because of the presence of multiple subtypes with potentially opposing effects. We therefore investigated the effect of long-term nicoti …
Although nicotine is well known to up-regulate alpha4* nAChR sites and function in the cortex, its actions in the striatum are uncertain bec …
Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M. Chen L, et al. Among authors: langston jw. Neuroscience. 2005;132(2):409-20. doi: 10.1016/j.neuroscience.2004.10.026. Neuroscience. 2005. PMID: 15802193
Long-term l-3,4-dihydroxyphenylalanine (L-DOPA) treatment in Parkinson's disease leads to dyskinesias in the majority of patients. ...
Long-term l-3,4-dihydroxyphenylalanine (L-DOPA) treatment in Parkinson's disease leads to dyskinesias in the majority of patients. .. …
Medulloblastoma metastatic to the suprasellar region at diagnosis: a report of six cases with clinicopathologic correlation.
Helton KJ, Gajjar A, Hill DA, Boop FA, Kun LE, Langston JW. Helton KJ, et al. Among authors: langston jw. Pediatr Neurosurg. 2002 Sep;37(3):111-7. doi: 10.1159/000064392. Pediatr Neurosurg. 2002. PMID: 12187055
In the present study, anatomic distribution and the signal characteristics and enhancement patterns of subtle anterior third ventricular recess metastases were compared with those of the original tumor; medical records were reviewed for clinical presentation, surgical stage, trea …
In the present study, anatomic distribution and the signal characteristics and enhancement patterns of subtle anterior third ventricular rec …
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group. Shoulson I, et al. Among authors: langston jw. Ann Neurol. 2002 May;51(5):604-12. doi: 10.1002/ana.10191. Ann Neurol. 2002. PMID: 12112107 Clinical Trial.
Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the long-term benefits of this treatment remain unclear. During 1987 to 1988, 800 patients with early Parkinson's disease were randomized in the Deprenyl and Tocopher …
Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the long-term benefits of …
23 results